- Home
- ARQT vs BANF Comparison
ARQT vs BANF Comparison
Compare ARQT & BANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- BANF
- Stock Information
- Founded
- ARQT 2016
- BANF 1984
- Country
- ARQT United States
- BANF United States
- Employees
- ARQT N/A
- BANF N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- BANF Major Banks
- Sector
- ARQT Health Care
- BANF Finance
- Exchange
- ARQT Nasdaq
- BANF Nasdaq
- Market Cap
- ARQT 3.3B
- BANF 3.6B
- IPO Year
- ARQT 2020
- BANF N/A
- Fundamental
- Price
- ARQT $28.01
- BANF $107.44
- Analyst Decision
- ARQT Strong Buy
- BANF Hold
- Analyst Count
- ARQT 7
- BANF 2
- Target Price
- ARQT $22.17
- BANF $128.00
- AVG Volume (30 Days)
- ARQT 3.1M
- BANF 109.1K
- Earning Date
- ARQT 10-28-2025
- BANF 10-17-2025
- Dividend Yield
- ARQT N/A
- BANF 1.81%
- EPS Growth
- ARQT N/A
- BANF 13.17
- EPS
- ARQT N/A
- BANF 7.04
- Revenue
- ARQT $317,929,000.00
- BANF $666,553,000.00
- Revenue This Year
- ARQT $85.27
- BANF $11.96
- Revenue Next Year
- ARQT $30.70
- BANF $3.80
- P/E Ratio
- ARQT N/A
- BANF $15.34
- Revenue Growth
- ARQT 129.21
- BANF 9.57
- 52 Week Low
- ARQT $9.19
- BANF $97.02
- 52 Week High
- ARQT $28.96
- BANF $138.77
- Technical
- Relative Strength Index (RSI)
- ARQT 71.06
- BANF 37.47
- Support Level
- ARQT $22.26
- BANF $105.70
- Resistance Level
- ARQT $24.39
- BANF $114.90
- Average True Range (ATR)
- ARQT 1.46
- BANF 2.83
- MACD
- ARQT 0.21
- BANF 0.31
- Stochastic Oscillator
- ARQT 85.67
- BANF 25.98
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About BANF BancFirst Corporation
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.